Latest Regulatory Filings News

Lodestar Minerals has responded to an ASX query over the late filing of director interest notices, attributing the delay to an administrative oversight during an option conversion process. The company has updated its procedures to prevent future lapses.

EQT’s controlled entity has upped its non-binding offer for Perpetual to A$22.07 per share, a 2% premium on its initial bid. The proposal hinges on Perpetual’s Wealth Management sale and other conditions, with no certainty of a deal.

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

Amaero has taken a key step toward listing in the US by confidentially submitting its draft registration statement to the SEC, though pricing and timing remain undecided.

Loyal Metals has cleared a key regulatory hurdle with ASIC registering the Scheme Booklet for its proposed A$0.45 per share acquisition by PT Bumi Resources. The Independent Expert endorses the deal as fair and reasonable, while Loyal’s board unanimously backs the scheme, setting the stage for a shareholder vote.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Kinetiko Energy is progressing rapidly from exploration to production with a major onshore gas discovery in South Africa, targeting first commercial compressed natural gas by late 2027 through a phased, capital-efficient development.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.